Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
An Open-Label, Pilot Study of Veliparib and Lapatinib in Patients With Metastatic, Triple-Negative Breast CancerBreast Cancer Res 2021 Mar 04;23(1)30, EM Stringer-Reasor, JE May, E Olariu, V Caterinicchia, Y Li, D Chen, DL Della Manna, GB Rocque, C Vaklavas, CI Falkson, LM Nabell, EP Acosta, A Forero-Torres, ES Yang
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.